通过协同性铁和脱硫来利用代谢漏洞来治疗乳腺癌

Yu Liang1, Haibo Lan2, Qiuyu Li2

  • 1Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.

PubMed
概括

这项研究引入了乳腺癌的双模式治疗方法,结合了铁和硫化,以克服治疗耐药性. 装有BAY876的新型Fe-Cu-SS金属有机框架 (MOF) 有效地准脂质过氧化和葡萄糖代谢,提高治疗结果.

相关概念视频

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K